MERCK Kommanditgesellschaft auf Aktien (0O14.IL)
| Previous close | 169.90 |
| Open | 169.75 |
| Bid | 168.35 x 0 |
| Ask | 171.85 x 0 |
| Day's range | 168.70 - 170.50 |
| 52-week range | 153.10 - 202.30 |
| Volume | |
| Avg. volume | 141,445 |
| Market cap | 73.496B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 20.99 |
| EPS (TTM) | 8.09 |
| Earnings date | N/A |
| Forward dividend & yield | 2.20 (1.34%) |
| Ex-dividend date | 02 May 2023 |
| 1y target est | N/A |
- Reuters
Merck KGaA expects 2023 profit to slip as COVID demand wanes
Germany's Merck KGaA on Thursday predicted 2023 earnings would slip due to a decline at its electronic chemicals unit and a drop in COVID-related demand for its lab supplies from drug and vaccine makers. For 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, the company "assumes a moderate decline to an about stable development", before any currency swings, it said in a statement. Negative foreign exchange effects would likely be an additional drag of between 1% and 4%, according to the maker of pharmaceuticals, lab equipment and specialty chemicals.
- Zacks
Bears are Losing Control Over Merck KGaA (MKGAF), Here's Why It's a 'Buy' Now
Merck KGaA (MKGAF) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
